Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Company Strategy - Medical Diagnostic Device Development
Compact Photonic Explorer (CPE) A smallscale spectroscopic diagnostic “pill” designed to detect optical molecular signatures of cancer inside the digestive tract of the human body.
CD-Ratiometer (CD-R) A medical device based upon optical spectroscopy without removing tissue from the body. Using patented algorithms, the CD-R will enable the OB/GYN to determine malignant, dysplastic and benign tissues of the Cervix.
Mediscience Technology Corporation has invested over $25 million in the development of noninvasive medical diagnostic devices that utilize ultraviolet light to detect the presence of cancer in human tissue. The company benefits from a separately funded research agreement with the City University of New York covering medical and non-medical applications of photonics which has generated over 26 patents, including "Stokes-Shift Fluorescence Spectroscopy" for the detection of disease and physiological state of specimen; as well as exclusive US and worldwide license rights, prototype instruments, and seminal in-vitro and in-vivo preclinical and clinical data.
In addition to the fundamental technology for all of its products, which stems from its licensing agreements with the City University of New York, Mediscience also has a collaborative arrangement with Infotonics Technology Center, a collaborative, industry-led Microsystems R&D center. The Center is a consortium which includes Corning, Xerox, and Eastman Kodak; the State of New York; Federal Government agencies; and eighteen universities domiciled in New York State. Its goal is to create high technology businesses from its position as a world leader in photonics and microsystems innovation and commercialization. The center will commercialize Mediscience's Compact Photonic Explorer. (described below).
The company believes that all known competitors have a limited intellectual property position relative to itself. Furthermore, all use less sensitive technologies based on diffuse reflectance or on tissue excitation at wavelengths that do not optimally interrogate key native fluorescence (the basis for the company's technology).
Basis for Technology
The onset of carcinogenesis causes molecular and structural change in tissue which can be observed through differences in the fluorescence spectra between benign, precancerous, and cancerous tissue when the tissue is excited by ultraviolet light. This is the basis for Mediscience's non invasive optical biopsy technology utilized in its diagnostic instruments. Successful preclinical and clinical evaluations support the devices' real time results, sensitivity, and specificity.
Initial Products
Two cancer detection instruments developed by Mediscience render tissue removal unnecessary, produce real time results at the time of the procedure, detect cancerous and pre-cancerous lesions before any visual indication of tumor occurs, and have over a 90% accuracy rate.
They are:
The CD-Ratiometer determines malignant, dysplastic, and benign tissue in the cervix through optical spectroscopy. without removing tissue from the body. It is a diagnostic tool for point of tissue characterization of the cervix based upon the measurement of key fluorescence ratios. The CD Ratiometer has been perfected by a five person research team at the City University of New York (MTC shareholder). A six month pilot study utilizing the CD Ratiometer is about to commence.(FDA filing Jan 5, 2006). This will be followed by a pivotal study which should be completed within another 12-18 months.
The Compact Photonic Explorer is an ingestible pill that detects optical signatures of cancer as it courses through the gastrointestinal tract (US Patent IP MTC owned). The Compact Photonic Explorer utilizes ultraviolet light to remotely monitor the health of human tissue. The procedure is a noninvasive biopsy determined through spectroscopy. Infotonics, Mediscience's collaboration nano-technology partner (MTC shareholder), on this project, estimates that it will have a production prototype of the Compact Photonic Explorer, within 12-18 months. The Center has the capability to ramp up to pre-commercial pilot production of thousands of devices.
Since the CD Ratiometer is essentially non-invasive in nature and does not cause physiological changes in tissue, it is reasonable to believe that the clinical studies should not be unnecessarily delayed because they will be replicating the highly accurate in-vitro and in vivo results already achieved.
In the case of the Compact Photonic Pill, the outer definition of the device is essentially similar to the Camera Pill currently being marketed by Givens (symbol GIVN) for taking pictures of the gastrointestinal tract. Mediscience has at its disposal the intellectual and fabricating capabilities in the area of Photonics of Infotonics Technology Center to miniaturize and create a production prototype which they estimate will be completed in 12-18 months. No great "leaps of technology" are required. The task of clinical trials will be to confirm the inclusion in the Compact Photonic Explorer of already proven technology to identify abnormal tissue in the gastrointestinal tract.
Exit Strategy
After a long gestation phase, Mediscience is now in a position to capitalize with a high degree of predictability on its broad based technology platform. Well defined programs for the Compact Photonic Pill and the CD Ratiometer make many options available for an exit strategy within a short period of time. These include:
A public offering with listing on a major exchange.
Licensing agreement with a major pharmaceutical/medical device company.
Marketing agreement with a company that has distribution capability to be served by Mediscience products
Acquisition by potential competitor or one with complimentary products.
The next phase of funding is intended to complete the pilot study for the CD Ratiomenter and see the Compact Photonic Pill through to a production prototype. As previously stated, these events should occur within a period of 18 months.
The pilot study for the CD Ratiometer will be completed within six months subsequent to funding. This is a significant milestone within the 18 month time frame mentioned above since it will trigger a pivotal study which should take an additional 12-18 months. As previously mentioned, the Infotonics Technology Center has expressed its confidence in delivering a production prototype of the Compact Photonic Pill with 12-18 months.
Company History - 1988 through 1998
Mr. Peter Katevatis, Chairman and CEO of Mediscience Technology, identified medical optics as a high potential area.
To pursue potential opportunities in this arena of technology, Mediscience Technology acquired Laser Diagnostics Instruments (LDI) and its seminal photonics patent, Method and Apparatus for Detecting Cancerous Tissue Using Visible Luminescence, from Dr. Robert Alfano.
Under the guidance of Mr. Katevatis, the company entered into a long-term research relationship with the City University of New York and Dr. Alfano (Distinguished professor of Science and Engineering, and director New York State Center for Advanced Technology for Ultra fast Materials and Lasers).
1988 through 1998
Mediscience Technology funded research at the City University, generating over 30 patents in the areas of tissue spectroscopy and optical imaging with applications in cancer detection.
The company also partnered with and/or conducted research at leading medical institutions including the National Cancer Institute (NCI), Memorial-Sloan Kettering Cancer Center, New York Hospital Cornell Medical Center, Yale University Department of OBGYN, and others. Its technology was validated in both pre-clinical and clinical testing, progressing to a focus on commercialization.
1998 through 2003
A research team, headed by Dr. Robert R. Alfano, at City College's Institute for Ultrafast Spectroscopy and Lasers (IUSL), developed a significantly more sensitive technique than conventional fluorescence Spectroscopy to detect cancerous bio-molecules and structures.
Named Stokes Shift Emission Spectroscopy, this method evolves from seminal work performed at the IUSL for the past two decades. Dr. Alfano affirmed, "this revolutionary breakthrough will make optical biopsy the new medical frontier for cancer diagnosis and other medical applications."
2004
Mediscience Technology enters into a project agreement for the development of cancer detection and diagnosis devices with the Research Foundation of the City University of New York.
As stated in a dramatic news release dated May 2, 2004:
" … this Project Agreement provides the Company with a clear path in its intent to commercialize the CD Ratiometer for detecting and diagnosing cancers of the cervix, mouth, esophagus and gastro intestinal tract and other potential applications that are compatible with current state of the art computer hardware and operating systems.We expect to have a completed device by November 30, 2004".
RF-CUNY completes production of the improved CD-Ratiometer instrument(s). Mediscience Technology seeks approval by the United States Food and Drug Administration (FDA) for marketing in the U.S.
RF-CUNY successfully applies its research and development to deliver an updated CD-Ratiometer, as well as associated technology for use in Mediscience Optical Biopsy, including the testing of the Mediscience CD-Ratiometer on ex vivo human tissue specimens.
Under the specific terms of the project agreement, Mediscience Technology is granted an exclusive world-wide license, with the right to grant sublicenses, to manufacture, use, or sell all patented imaging product technology for molecular detection of cancer and physiological change.
Mediscience has good fundamentals, I hope to see great things from this company. imo
I have been following this company for a while, they design and develop cancer detecting devices.
Company Officers
Peter Katevatis, CEO
Michael W. Engelhart, President, COO
John Kennedy, CFO
Mediscience Technology Corporation is engaged in the design and development of diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy (the "Technology") to distinguish between malignant and normal or benign tissue
VGTel operates virtual platform supporting world-wide telecommunication services. The company expands and penetrates new market segments while setting-up a global chain of franchise operations to promote its services in each local region.
good afternoon, welcome to the VGTel, Inc Board
After doing some DD on the company, I see good fundamentals. imo
PR's updated!
Currently hold 2 patents.
No. US 6,975,220 B1, "Internet Based Security, Fire and Emergency Identification and Communication System,"
No. US 7,302,481 B1, "Methods and Apparatus Providing Remote Monitoring of Security and Video Systems,"
Latest PR - PROTALEX, INC. TO PRESENT AT RODMAN & RENSHAW 10TH ANNUAL HEALTHCARE CONFERENCE
NEW HOPE, Pa., Nov 03, 2008 (BUSINESS WIRE) -- Protalex, Inc. (OTCBB:PRTX) today announced that Steven H. Kane, President and Chief Executive Officer, will present at the upcoming Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 3:40 p.m. Eastern Time. The event will be held from November 10-12, 2008 at the New York Palace Hotel in New York.
Individuals may listen to a live webcast of the presentation by logging on to the Investors section of Protalex' web site, www.protalex.net, a few minutes prior to start time. The presentation will be archived for 90 days.
The conference will feature presentations from more than 350 public and privately held emerging growth healthcare companies presenting data on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. Details regarding the conference can be obtained at www.rodmanandrenshaw.com.
About PRTX-100
PRTX-100 is a highly-purified form of the Staphylococcal bacterial protein known as Protein A. PRTX-100 has the ability, at very low concentrations, to bind to and to down regulate activation of human B-lymphocytes and macrophages which are key cells mediating inflammation in certain autoimmune diseases. Laboratory studies indicate the mechanism involves interference with specific intracellular signaling pathways. Pre-clinical studies also demonstrate that very low doses of PRTX-100 have potent therapeutic effects on model inflammatory diseases.
About Protalex, Inc.
Protalex, Inc. is a biotechnology company engaged in the development of a new class of drugs for the treatment of rheumatoid arthritis, idiopathic thrombocytopenic purpura and a host of other autoimmune disorders. Additional information about Protalex, Inc. can be found at www.protalex.com.
Cautionary Statement Regarding Forward Looking Information
This release contains forward-looking information about Protalex, Inc. that are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and Protalex's future performance, operations and products.
This forward-looking information should be considered only in connection with "Risk Factors" in Protalex's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on August 29, 2008 and its other periodic reports filed with the SEC. Protalex assumes no obligation to update any forward-looking statements or information set forth in this press release.
PRTX-G
SOURCE: Protalex, Inc.
Protalex, Inc.
Marc L. Rose
Vice President and Chief Financial Officer
(p) 215-862-9720
(f) 215-862-6614
mrose@protalex.com
Copyright Business Wire 2008
News Provided by COMTEX
http://investor.protalex.com/ReleaseDetail.cfm?ReleaseID=345020
I see strong fundamentals in this company. imo
Latest PR - ComCam to Be Featured in Trade Mission to Saudi Arabia
Monday September 29, 8:15 am ET
WEST CHESTER, Pa., Sept. 29 /PRNewswire-FirstCall/ -- ComCam International Inc. (OTC Bulletin Board: CMCJ - News), a technology innovator in IT surveillance products and solutions, will participate with the State of Pennsylvania's official trade mission to Saudi Arabia, November 1 to 3, 2008.
ADVERTISEMENT
Don Gilbreath, ComCam's CEO, announced that "we have retained the services of Peter Alois to spearhead our business development efforts in the Middle East." Alois, a retired U.S. career diplomat with extensive experience in the Middle East, will head-up ComCam's efforts throughout the Persian Gulf. He was assigned to the U.S. Embassy in Kuwait as the Commercial Counselor, and twice journeyed to Iraq in 2004 to develop business for American industry.
Gilbreath and Alois have already briefed the U.S. Embassy in Baghdad and the Embassy of the Sultanate of Oman in Washington, D.C. on ComCam's unique capabilities. For the November mission, appointments to meet business leaders are scheduled in Saudi Arabia. While in the Middle East, the group will also visit Kuwait and other Gulf nations to identify new business opportunities and prospective sources for investment capital.
Gilbreath extended his appreciation to the groups that are organizing this mission: "We thank the State of Pennsylvania and the U.S.-Saudi Arabian Business Council for inviting ComCam, the only security-related company to participate in this important official delegation."
ComCam develops remote network devices and services that are used, shared, managed and re-deployed throughout numerous divergent industries. Applications are in the security, environmental and tele-medical areas.
A number of statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended. A safe-harbor provision may not be applicable to the forward-looking statements made in this press release because of certain exclusions under Section 27A (b). These forward-looking statements involve a number of risks and uncertainties, including timely development, market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions and the ability to secure additional sources of financing. The actual results that ComCam may achieve could differ materially from any forward-looking statements due to such risks and uncertainties. ComCam encourages the public to read the information provided here in conjunction with its most recent filings on Form 10-KSB and Form 10-Q. ComCam's public filings may be viewed at http://www.sec.gov.
For additional information about ComCam and the trade mission, please contact:
Peter Alois, Business Development Middle East
tel. - 610.455.3960
David Rosen, VP Corporate Development
tel. - 610,436.8089
http://www.comcam.net
http://biz.yahoo.com/prnews/080929/nem053.html?.v=60
The Market for Mobility
The business mobility space is currently a $104 billion market and is projected to grow at a 12 percent CAGR through 2012. Due to the rapid pace of technological change and the emergence of many vendors with varied messages, the market is highly fragmented and extremely difficult for potential buyers to navigate. Small to medium-sized businesses (SMBs), estimated to number more than 6 million, face the greatest challenges since they typically do not have comprehensive IT departments and are underserved by industry leaders focused on the large-enterprise market.
MacroSolve, with experience serving the SMB customer, expertise in total mobile solutions, and strong industry partnerships, is uniquely positioned to help SMB buyers manage the market and make informed, efficient, effective buying decisions.
http://www.macrosolve.com/strategy.html
New PR's Posted!
MacroSolve Strategy
Founded in 1996, MacroSolve was at the forefront of mobile computing and was one of Palm Inc.'s very first development partners. Since the 2002 launch of its Anyware Mobile Solutions division, MacroSolve has gained deep experience and secured a unique position as both a solutions provider and a hub for partners in multiple segments of the industry. The company's strategies build on this foundation.
http://www.macrosolve.com/strategy.html
http://www.goanyware.com/index.asp
Resources:
30 Full time employees
HQ in Tulsa, Oklahoma
Offices in Dallas, Texas
http://www.macrosolve.com/docs/MacroSolve_Profile_Sept08_Online.pdf
Financial Summary:
Revenues FY 2007: $2.3M
Gross Margin FY 2007: 50%
Revenues Q2 2008: $667.9K
Gross Margin Q2 2008*: 45%
Cash on Hand Q2 2008: $414.6K
http://www.macrosolve.com/docs/MacroSolve_Profile_Sept08_Online.pdf
- 66% revenue growth FY 2007 – FY 2006
- Revenue growth driven by increasing demand from both new customers
and current customers
- Customer base is underserved market in fragmented industry
- $104 B market growing at 12% CAGR
- Long standing relationships with market leaders
- 12th year of operations
http://www.macrosolve.com/docs/MacroSolve_Profile_Sept08_Online.pdf
MacroSolve, Inc., through its Anyware Mobile Solutions division, is a leading
provider of mobile data and mobile video solutions to businesses. MacroSolve
delivers the bottom-line benefits of mobility to all businesses while specializing
in the small and medium-sized business (SMB) niche. The Company has been a
pioneer in the rapidly expanding business mobility market, a $104 B subset of the
$600 B telecommunications market. The Company’s revenues grew to $2.3 M in
2007, a 66% increase over fiscal 2006 revenues of $1.4 M while capturing gross
margins of 50%.
Serving the growing demand for mobile business solutions, MacroSolve has
strategically positioned itself as the hub of expertise for enabling mobility.
MacroSolve brings together the demand - business customers seeking mobile
solutions – with the supply - mobile technology companies seeking to package and
sell their products to business customers. Leveraging its experience and position,
MacroSolve’s strategy is to springboard into higher-margin, recurring revenue
streams through the upcoming launch of the industry’s first online mobile business
solutions community and e-marketplace.
http://www.macrosolve.com/docs/MacroSolve_Profile_Sept08_Online.pdf
Good afternoon
NEW PR! 11/18/08 CORRECTING and REPLACING MVP Network Inc. Inks $12 Million Marketing Deal With edaddywarbucks Inc.
ST. LOUIS, Nov 18, 2008 (BUSINESS WIRE) -- Throughout the release, MPV Network Inc. should read MVP Network Inc.
The corrected release reads:
MVP NETWORK INC. INKS $12 MILLION MARKETING DEAL WITH EDADDYWARBUCKS INC.
MVP Network Inc. (OTC:MVPN.OB), developer of interactive sports video games, announced today that it has signed a $12 million marketing agreement with edaddywarbucks Inc. Sacramento-based edaddywarbucks Inc. is a strategic marketing company that facilitates barter arrangements with national media to build brand awareness and consumer acceptance of publicly traded companies.
"This agreement fits in extremely well with our long-term business strategy and allows us to expedite our marketing campaign," said Paul Schneider, president and founder of MVP Network, Inc.
MVP Network, Inc. is a developer of interactive video games and gaming websites. The company's games run on standard personal computers and do not require specialized interfaces or proprietary hardware. Gamers can experience real-time completion with people all over the world, in such competitive sports as golf, poker, soccer and automobile racing. In addition, MVP Network, Inc. offers sale of in-game advertisements and provides opportunities for game tournaments and video game fundraising.
"I am very excited to be involved with such a progressive and cutting edge company involved in the exciting online video game industry," said Norm Alvis, president and founder of Sacramento, California-based edaddywarbucks.
For more information about MVP Network Inc. visit http://www.mvpnetwork.com.
About MVP Network Inc.
MVP Network Inc. is a 14-year old company that develops multi-player games for global distribution. The company's specialty is developing online, 3D multiplayer sport games including golf, soccer, and American Stock Car and Grand Prix style racing games, and offering in game advertising and sponsorship opportunities.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, further events or otherwise.
SOURCE: MVP Network Inc.
MVP Network Inc.
Paul Schneider, 314-241-0070
support@TheMVPNetwork.com
http://www.mvpnetwork.com/company.cfm
Copyright Business Wire 2008
http://www.marketwatch.com/news/story/CORRECTING-REPLACING-MVP-Network-Inc/story.aspx?guid=%7B85097AE8-4F4E-47C0-A9E6-C9BE6C7FF838%7D
seeker, I have been on the phone with "Haji" when I called dell tech support! LOL Yes, chinese manufacturing is nothing new.
imo
Rokwader, Inc.
Clearview Acquisitions, Inc.
good afternoon
waiting on new PR
this has some momo today. imo
November, 2008
Octavian International completes $13 million private placement and merges into public shell
London, UK – November 5th, 2008 – Octavian International Ltd. (“Octavian”), a leading provider of total gaming and lottery solutions, serving Casino, AWP (Amusements With Prizes), Lottery and emerging gaming market sectors worldwide, announced today that on October 30, 2008 it completed a reverse merger with HouseFly, Inc., a publicly traded shell company (OTC BB: HSLY) (the “Company”). Upon closing of the reverse merger, the Company changed its corporate name to Octavian Global Technologies, Inc.
Contemporaneous with the reverse merger, the Company completed a private placement to certain accredited institutional investors for gross proceeds of $13 million. Pursuant to the private placement the Company issued, in the aggregate, $14,285,700 principal amount of Original Issue Discount Convertible Debentures due October 30, 2011 with a term of three years and a conversion price of $3.10, five-year common stock purchase warrants to purchase up to 2,096,774 shares of common stock with an exercise price of $3.10 per share, seven-year common stock purchase warrants to purchase up to 2,096,774 shares of common stock with an exercise price of $4.65 per share and 4,624,327 shares of common stock. Other than the 4,624,327 shares of common stock, the prices and numbers of shares issuable pursuant to the debentures and warrants will not be adjusted for an anticipated 5.0174 for 1 reverse stock split.
At the closing of the reverse merger, the Company issued to Octavian’s stockholders 30,773,387 shares of the Company’s common stock, representing approximately 78.6% of the post-financing issued and outstanding shares of the Company, in exchange for all of Octavian’s outstanding ordinary shares. Additionally, the Company issued to certain advisors five-year common stock purchase warrants to purchase up to, in the aggregate, 335,484 shares of common stock with an exercise price of $3.10. In addition, the Company issued 2,720,833 seven-year common stock purchase warrants with an exercise price of $3.10 per share to management of the Company.
Octavian has 39,147,714 shares of common stock issued and outstanding immediately following the reverse merger and financing described above.
Feldman Weinstein & Smith LLP acted as legal counsel for the Company in the reverse merger.
Harmen Brenninkmeijer, CEO of Octavian and the Company, stated: “This transaction allows us to forge ahead with many exciting opportunities that we have been planning and developing for some time. It also allows us to invest further in solution development – such as our Maverick EGM brand, our games kits and our e2e GMS (End to End Gaming Management System). This will enable us to invest in our customers’ future success by working with operators to maximize the business benefits of our new Octavian EasyStart casino system.”
Brenninkmeijer added: “Our strategy has always been to seek out and nurture opportunities in growth markets across the gaming world. Now, with strong backers, we can capitalise on those opportunities and take Octavian to the next level. Nevertheless, our core positioning as a strong and innovative, technology-focused company remains unchanged. We will continue to grow our technologies into major business-building pipelines, through which our customers can manage their gaming operations and generate and deliver business success.”
The securities issued in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws, and accordingly may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
About Octavian Global Technologies Inc www.octavianinternational.com
Established in 2001, Octavian is a leading provider of total gaming and lottery solutions, serving Casino, AWP (Amusements With Prizes), Lottery and emerging gaming market sectors worldwide. Octavian-developed solutions, and also leading third-party products, are marketed under four core solution areas – OctaSystems, OctaGames, OctaSupplies and OctaLotto. The company currently has offices and computer centres in the Argentina, Australia, Colombia, Germany, India, Italy, Russia, UK, Ukraine and USA. Through this extensive network, and also through joint ventures and partnerships across the gaming world, Octavian systems, games and other solutions are deployed and supported in more than 30 countries.
For further information contact:
Helen Hedgeland
+44 (0) 1483 543 543 or
Mail H.Hedgeland@octavianinternational.com
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. Factors that may affect these forward-looking statements include, among others, our ability to raise capital, the decisions of third parties over which we have no control, the state of the telecommunications industry, technological changes and other factors set forth from time to time in our public statements. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date of this news release.
http://www.octavianinternational.com/news_details.asp?nid=113&id=31
Nov 13, 2008 Form 10-Q for POP STARZ RECORDS, INC.
http://biz.yahoo.com/e/081113/pszr.ob10-q.html
Guru, your the moderator go to the website and get the number yourself. In all actuality your the board secretary so get moving. imo
Founder of THe Quad.com Zach Suchin
http://v2.b96hiphop.com/avc-view.aspx?videoid=214&categoryid=2
I see a lot of potential here and great fundamentals. imo
Good afternoon!
Welcome to the Accuride Corp. board!
Good Morning